Trastuzumab Rezetecan Plus Camrelizumab for Bladder Cancer Surgery
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests a combination of two drugs (trastuzumab rezetecan and camrelizumab) given before and after surgery to remove the bladder in patients with HER2-positive muscle-invasive bladder cancer. The goal is to improve survival and reduce cancer recurrence in this aggressive type of bladder cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 18 or older with confirmed bladder urothelial carcinoma (a specific type of bladder cancer)
- Cancer is muscle-invasive (has grown into the muscle layer) and confined to the pelvis with no spread to distant organs
- Tumor must test positive for HER2 protein (a growth-promoting marker)
- Good overall health (ECOG score 0–1) and able to tolerate surgery and chemotherapy
- Candidate for radical cystectomy (surgical removal of the entire bladder)
- Adequate organ function: normal blood counts, liver, kidney, and heart function (heart ejection fraction ≥50%)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two new drugs (trastuzumab rezetecan and adebrelimab) given before surgery to remove bladder cancer. The drugs target HER2, a protein found on some bladder cancer cells, and may help shrink tumors and improve surgery outcomes.
This trial tests combining two newer drugs (zanidatamab and tislelizumab) with standard chemotherapy before bladder surgery. The goal is to shrink the tumor so the bladder can be saved instead of removed.
This trial tests a combination of two drugs (eribulin and toripalimab) given before surgery to remove bladder cancer. The goal is to shrink the tumor and improve outcomes for people with advanced or high-risk bladder cancer.
This trial tests a new drug combination for people with advanced bladder cancer that has a protein called HER2 on its surface. It may help those whose cancer has spread or cannot be removed with surgery. The study looks at the drug given alone or with an immunotherapy.
This trial tests a new antibody-drug (RC48-ADC) together with an immunotherapy medicine (triplizumab) given before bladder surgery. It’s for people with HER2-positive muscle-invasive bladder cancer who may benefit from shrinking the tumor before radical cystectomy.
This trial tests a combination of two drugs—an antibody-drug conjugate (Disitamab Vedotin) and an immunotherapy (Toripalimab)—given for different lengths of time to treat muscle-invasive bladder cancer. The goal is to preserve the bladder while controlling the cancer.
Hear when a new Urinary Bladder Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.